Catalyst Oncology

( Thomas Jefferson University ) With a pre-emptive, prophylactic skin regimen, patients who receive panitumumab for treatment of metastatic colorectal cancer may be able to avoid some of the skin-associated toxicities according to data presented at the 2009 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

Here is the original: 
Pre-emptive treatment helped curtail skin toxicity with panitumumab (EurekAlert!)